We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The pressure keeps mounting on Mylan for its EpiPen pricing practices, and now the New York attorney general’s office is investigating whether Mylan engaged in anticompetitive practices when entering contracts to sell its allergy therapy EpiPen to schools. Read More